HealthQuill AstraZeneca Plc.
AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish drugmaker.
Uncategorized

EU panel gives a positive opinion for AstraZeneca’s cancer drug

AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish.

Read More
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs Health Pharma

AstraZeneca’s medicine to treat a type of breast cancer gets US nod

AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.

Read More
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from the Japanese company.
Drugs Health Pharma

Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.

Read More
The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.
Drugs Medical Pharma

AstraZeneca’s drug gets nod to treat limited-stage cell lung cancer patients

The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.

Read More
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of 2026, according to a company statement.
Drugs Health Pharma

AstraZeneca to invest $3.5 billion in the US to expand global footprint

Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of.

Read More
AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s drug to treat rare blood vessel disease gets EU nod

AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.

Read More
AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of breast cancer in the US.
Drugs Health Pharma

AstraZeneca, Daiichi’s Enhertu drug gets FDA’s priority review in US

AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.

Read More
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an end-stage trial, according to a joint statement.
Drugs Health Pharma

AstraZeneca-Daiichi Sankyo’s breast cancer drug fails in late-stage trial

British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.

Read More
The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s rare disease drug Fasenra gets US regulator’s nod

The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.

Read More
China’s drug regulator, the National Medical Products Association, has approved AstraZeneca Plc’s asthma drug.
Drugs Health Pharma

AstraZeneca’s asthma drug gets regulator’s approval in China

China’s drug regulator, the National Medical Products Association, has approved  AstraZeneca Plc’s asthma drug.

Read More